The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study
Abstract Background 223Ra is currently used for treatment of metastatic castration resistant prostate cancer patients (mCRPC) bone metastases with fixed standard activity. Individualized treatments, based on adsorbed dose (AD) in target and non-target tissue, are absolutely needed to optimize effica...
Main Authors: | Rosa Sciuto, Sandra Rea, Sara Ungania, Antonella Testa, Valentina Dini, Maria Antonella Tabocchini, Clarice Patrono, Antonella Soriani, Valentina Palma, Raffaella Marconi, Lidia Strigari |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-09-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13046-021-02056-9 |
Similar Items
-
Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC
by: Viviana Frantellizzi, et al.
Published: (2020-10-01) -
Dosimetry-Based Consideration on Remission and Relapse after Therapy with 223Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report
by: Anna Maria Mangano, et al.
Published: (2018-02-01) -
Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
by: Roviello G, et al.
Published: (2018-12-01) -
Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration-resistant prostate cancer
by: Vera Höllriegl, et al.
Published: (2021-06-01) -
Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Iván Henríquez, et al.
Published: (2021-09-01)